Navigation Links
ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
Date:8/27/2007

ImmuneRegen and TGen Continue Testing Possible Treatment for Acute Radiation Syndrome or Radiotherapy Adjuvant Likely Targeting Adult Stem

Cells in Bone Marrow

SCOTTSDALE, Ariz., Aug. 27 /PRNewswire-FirstCall/ -- ImmuneRegen BioSciences, Inc., a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTC Bulletin Board: IRBO), today announced that initial studies at TD2 (TGen Drug Development Services), an affiliate of The Translational Genomics Research Institute (TGen) have found ImmuneRegen's Radilex (TM) to protect mice from the near total destruction of circulating white blood cells following radiation exposure. These findings support past data and provide further insight into possible mechanisms underlying the activity of Radilex as well as suggest possible therapeutic areas in which Radilex could play a role as a potential treatment.

In previous studies of lethally irradiated mice, Radilex was shown to enhance survival and increase white blood cells in surviving animals. In the recent studies, a sub-lethal dose of radiation induced a 90-95% decrease in circulating white blood cell levels. Administered shortly following radiation exposure, Radilex was able to subsequently increase circulating levels of monocytes, granulocytes and lymphocytes in all treated animals.

"The results of this study have strengthened our confidence that Radilex(TM) may prove to be a life saving treatment candidate as well as a drug and treatment enhancement candidate," says Michael K. Wilhelm, Co-Founder and CEO of ImmuneRegen BioSciences, Inc. "We are very happy that our relationship with TGen continues to develop a promising collection of data on Radilex's ability to potentially preserve human life after lethal or sub-lethal exposure to radiation."

Low circulating white blood cell counts (leukopenia or leukocytopenia) can be due to a number of causes, among them infections (including certain viral infections such as
'/>"/>

SOURCE ImmuneRegen BioSciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ImmuneRegen BioSciences Announces Promising Data on Homspera Suggesting Potential as a Co-Therapeutic Agent
2. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials
3. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
4. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
5. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
6. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
7. Gerons Telomerase Inhibitor Cancer Drug Demonstrates Good Pharmacokinetics and Tolerability in Phase I/II Trial
8. Frova Phase III Study Data Demonstrates That Short-Term Prevention Treatment Reduces Frequency and Severity of Menstrual Migraine
9. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
10. Cipralex demonstrates superiority to duloxetine for acute treatment of depression in new study
11. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... 2015 Research and Markets ( ... "The Corporate Reputation of Pharma - The ... report to their offering. The ... now in its fourth edition. This report contains ... For each annual Corporate Reputation report, the author ...
(Date:4/16/2015)... , April 16, 2015 Vanda Pharmaceuticals Inc. ... on the development and commercialization of products for the ... will release results for the first quarter of 2015 ... The Company will host a conference ... 2015, during which Vanda management will discuss the first ...
(Date:4/16/2015)... 2015  Amgen (NASDAQ: AMGN ) today announced ... on Tuesday, April 21, 2015, after the close of ... by a conference call with the investment community at ... will be Robert A. Bradway , chairman and ... management team. Live audio of the conference ...
Breaking Medicine Technology:The Corporate Reputation of Pharma - The Global Patient Perspective in 2014 2Vanda Pharmaceuticals to Announce First Quarter 2015 Financial Results on May 6, 2015 2Amgen Announces Webcast Of 2015 First Quarter Financial Results 2
... SCOTTSDALE, Ariz., Feb. 14, 2012  Cayenne Medical, Inc., a ... of a $10 million equity financing, with new investor ... MB Venture Partners and Investor Growth Capital. The proceeds ... distribution and to support expansion of its portfolio of ...
... 2012 Leading events organiser UBM Live , a ... of Jim Buckley as the new Brand Director for Informex. ... value chemistry via a comprehensive calendar of conferences and events, ... is run in partnership with the Society of Chemical Manufacturers ...
Cached Medicine Technology:Cayenne Medical Closes $10 Million Capital Raise 2UBM Live Appoints Jim Buckley as Informex Brand Director 2UBM Live Appoints Jim Buckley as Informex Brand Director 3
(Date:4/19/2015)... York (PRWEB) April 19, 2015 New ... Multidistrict Litigation (JPML) indicate that Lipitor lawsuits ( http://www.lipitorlawsuitcenter.com/ ... in U.S. District Court, District of South Carolina. According ... cases have been filed in the proceeding on behalf ... to their use of the cholesterol-lowering statin. This represents ...
(Date:4/19/2015)... Hanover, MA (PRWEB) April 19, 2015 Family ... Bowling for Brains in Memory of Brad Baddeley ... renowned Brain Aneurysm Foundation. , Bowling for Brains is cheduled ... Bowling located 4700 Dudley Street in Lincoln, Nebraska. Participants may ... from 1:00 to 3:00pm. , The cost is only $4 ...
(Date:4/18/2015)... Carinsurancequotesinfo.com has released a new blog post explaining ... caused by a car accident. , Car insurance ... A policy can pay for car repairs and even ... carry appropriate coverage when they are driving. ... several important riders that offer extra coverage options. One ...
(Date:4/18/2015)... Review of Ophthalmology magazine and Abbot Medical ... program for cataract surgeons attending the American Society of ... eye surgeon Jeffrey L. Martin, MD will serve as ... is the Managing Partner of North Shore Eye Care. ... to lead this year’s discussion on the latest breakthroughs ...
(Date:4/18/2015)... 18, 2015 Thousand of DePuy Pinnacle ... of individuals who were allegedly harmed by a metal-on-metal ... forward in the U.S. District Court, Northern District of ... Court has amended an earlier Case Management Order to ... things, the new amendment permits the claims of up ...
Breaking Medicine News(10 mins):Health News:Lipitor Lawsuits Mount, as New Court Report Shows More Than 100 Filings Added to Federal Litigation Since March 2Health News:Lipitor Lawsuits Mount, as New Court Report Shows More Than 100 Filings Added to Federal Litigation Since March 3Health News:Lincoln, NE’s Bowling for Brains to benefit Renowned Brain Aneurysm Foundation 2Health News:Lincoln, NE’s Bowling for Brains to benefit Renowned Brain Aneurysm Foundation 3Health News:Auto Insurance Plans Can Cover Physical Injuries Caused By An Accident! 2Health News:Dr. Jeffrey Martin Invited to Share Latest Breakthroughs in Cataract Care During Roundtable Discussion at National 2015 ASCRS Meeting In San Diego 2Health News:DePuy Pinnacle Hip Lawsuits: Federal Litigation Amends Case Management Order to Allow for Joinder of Unrelated Claims 2Health News:DePuy Pinnacle Hip Lawsuits: Federal Litigation Amends Case Management Order to Allow for Joinder of Unrelated Claims 3
... 10, 2007 The sleep patterns of patients in ... barely spend any time in the restorative stages of ... physicians have found. , Current clinical-care protocols routinely and ... time when the need for adequate rest is perhaps ...
... Overall Survival Advantage in Elderly Myeloma ... Added to Standard Therapy - Data Presented at ... Dec. 9 Pharmion Corporation (Nasdaq:,PHRM) today announced final ... that the addition of,Thalidomide to standard treatment improves survival ...
... - Two drugs approved for use as second line therapy ... therapy for newly diagnosed patients in two clinical trials, research ... D. Anderson Cancer Center report at the 49th annual meeting ... patients in both trials have a complete cytogenetic response - ...
... Health & Science University Cancer Institute researchers have opened a ... , We are looking under the surface of CML to ... have discovered abnormal cells in the early stem cell population ... clone. These are abnormal cells that are not part of ...
... off going to the doctor or overindulge in unhealthy ... -- The holiday season is also the season for ... of the Vanderbilt Heart and Vascular Institute at Vanderbilt ... Churchwell, a look at a U.S. database of 53 ...
... GA, December 8, 2007 -- Results from two investigational ... bortezomib provide preliminary anti-tumor activity in patients with relapsed ... showed that 10 of 21 (48 percent) evaluable patients ... and bortezomib combination treatment. Data from a second ...
Cached Medicine News:Health News:Physicians seek to improve the quality of sleep in ICU, researchers at UT Southwestern report 2Health News:Thalidomide Added to Standard Therapy Prolongs Overall Survival in Newly Diagnosed Multiple Myeloma Patients Over Age 75 2Health News:Thalidomide Added to Standard Therapy Prolongs Overall Survival in Newly Diagnosed Multiple Myeloma Patients Over Age 75 3Health News:Thalidomide Added to Standard Therapy Prolongs Overall Survival in Newly Diagnosed Multiple Myeloma Patients Over Age 75 4Health News:Thalidomide Added to Standard Therapy Prolongs Overall Survival in Newly Diagnosed Multiple Myeloma Patients Over Age 75 5Health News:Thalidomide Added to Standard Therapy Prolongs Overall Survival in Newly Diagnosed Multiple Myeloma Patients Over Age 75 6Health News:Thalidomide Added to Standard Therapy Prolongs Overall Survival in Newly Diagnosed Multiple Myeloma Patients Over Age 75 7Health News:Dasatinib, Nilotinib show strong early results as frontline therapy for chronic myelogenous leukemia 2Health News:Dasatinib, Nilotinib show strong early results as frontline therapy for chronic myelogenous leukemia 3Health News:OHSU Cancer Institute research discovery opens new window to understanding chronic myeloid leukemia 2Health News:Heart Attacks Peak During the Holidays 2Health News:ZOLINZA (vorinostat) in combination with bortezomib demonstrated clinical activity 2Health News:ZOLINZA (vorinostat) in combination with bortezomib demonstrated clinical activity 3
... drainage from the ureteropelvic junction to the ... segment with no sideports prevents postoperative narrowing ... of the ureteral wall to the stent. ... one-time use. CAUTION: Periodic evaluation is advised; ...
... Whether you prefer silicone or ... Specialty Stents help promote healing after ... guards against anastomotic stricture, supports the ... the prevention of postoperative leakage. Following ...
... The Max-Blade™ Coagulating Resector is a device that ... This patented design was developed to provide the ... same high quality pathology chip, the approximate speed ... enjoyed with a standard loop but with ...
... Used for stone manipulation and removal in ... the basket to retain its shape following extreme ... stone capture by allowing the basket to open ... the stone. The tipless design reduces the likelihood ...
Medicine Products: